Evaluation of risperidone efficacy versus placebo in treatment of obsessive compulsive disorder symptoms in bipolar patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140926019295N3

Enrollment

Registered

2022-09-13

Start date

2022-08-23

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

?????? ?????? ????-?????? ??????. Obsessive-compulsive disorder

Interventions

Intervention 1: Intervention group: risperidone with initial dose 5mg for 12 weeks and at intervals of 4, 8, and 12 weeks, the level of obsessive symptoms will be evaluated using the Yale Brown questi

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: DSM-5 criteria for Bipolar disorder type 1 or 2 yale-brown score higher than 61 Coincidence of Bipolar disorder and obsessive-compulsive disorder

Exclusion criteria

Exclusion criteria: Acute phase of mania or depression Major medical conditions(cardiovascular-respiratory-renal-digestive) Pregnancy

Design outcomes

Primary

Measure	Time frame
Obsessional symptoms. Timepoint: 4 and 8 weeks after receiving risperidone. Method of measurement: yale brown questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahsa Ghavipisheh

Shiraz University of Medical Sciences

mghavipisheh@gmail.com+98 71 3647 9319

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026